NASDAQ · Biotechnology · USD

Ventyx Biosciences Inc (VTYX) Stock Analysis

Ventyx Biosciences Inc (VTYX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VTYX

$14.00

$0.00 (0.00%)

Last trade March 6, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VTYX with… →

VTYX Key Statistics

As of Mar 6, 2026

Trading

Open: $14.00
Previous Close: $14.00
52-Week Range: 0.78–25.00
Beta: 1.27

Valuation

Market Cap: $1.00B
P/E Ratio: unprofitable
EPS (ttm): −1.49

Financials (FY)

Profit margin: 0.00%
1-Year Return: +803.23%

Dividend and dates

Avg Volume: 3.62M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VTYX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−3.95%+312.33%+55.04%

2024*20252026*

Year	Return
2026 (partial year)	+55.04%
2025	+312.33%
2024 (partial year)	−3.95%

As of March 6, 2026.

VTYX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	VTYX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Ventyx Biosciences Inc (VTYX) is capitalised at $1.00B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 83 employees.

The most recent close on file for VTYX is $14.00, dated March 6, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.78 to $25.00. The latest close sits 1,687.99% above that 52-week low.

Financial Health

The reported profit margin is 0%. Trailing earnings per share are −1.49.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +803.23%. Beta against the wider market is reported at 1.27. Daily returns over the trailing 1 year annualize to a volatility of 123.47%.

Growth & Income

No dividend is on file for VTYX.

The record holds one complete calendar year, 2025, which returned +312.33%. So far in 2026 the price is +55.04%.

Peer Comparison

Ventyx Biosciences Inc (VTYX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Ventyx Biosciences Inc	VTYX	$1.00B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Ventyx Biosciences Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of March 6, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.

Visit website →